A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael J. Millward, Wei Zhang, Ling Gao, Amanda Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, Kris Anne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. GordonRamon V. Tiu, David S. Hong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors. This multicenter, open-label, phase I clinical trial (NCT02014116) consisted of part A (dose escalation) and part B (dose confirmation) in patients with advanced/metastatic cancer. In part A, oral LY3009120 was dose escalated from 50 to 700 mg twice a day on a 28-day cycle. In part B, 300 mg LY3009120 was given twice a day. The primary objective was to identify a recommended phase II dose (RP2D). Secondary objectives were to evaluate safety, pharmacokinetics, and preliminary efficacy. Identification of pharmacodynamic biomarkers was exploratory. In parts A and B, 35 and 16 patients were treated, respectively (N = 51). In part A, 6 patients experienced eight dose-limiting toxicities. The RP2D was 300 mg twice a day. Common (>10%) any-grade drug-related treatment-emergent adverse events were fatigue (n = 15), nausea (n = 12), dermatitis acneiform (n = 10), decreased appetite (n = 7), and maculopapular rash (n = 7). The median duration of treatment was 4 weeks; 84% of patients completed one or two cycles of treatment. Exposures observed at 300 mg twice a day were above the preclinical concentration associated with tumor regression. Eight patients had a best overall response of stable disease; there were no complete or partial clinical responses. Despite adequate plasma exposure levels, predicted pharmacodynamic effects were not observed.

Original languageEnglish
Pages (from-to)460-467
Number of pages8
JournalMolecular Cancer Therapeutics
Volume19
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

Fingerprint Dive into the research topics of 'A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer'. Together they form a unique fingerprint.

  • Cite this

    Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Rodon Ahnert, J., Millward, M. J., Zhang, W., Gao, L., Sykes, A., Willard, M. D., Yu, D., Schade, A. E., Crowe, K. A., Flynn, D. L., Kaufman, M. D., Henry, J. R., Peng, S. B., Benhadji, K. A., Conti, I., ... Hong, D. S. (2020). A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Molecular Cancer Therapeutics, 19(2), 460-467. https://doi.org/10.1158/1535-7163.MCT-19-0681